FDA advisory panel recommends Pfizer vaccine for kids ages 5 to 11
A panel of independent advisers to the Food and Drug Administration is recommending that the agency issue an emergency use authorization for the Pfizer-BioNTech vaccine in children ages 5 to 11 years old. The vote was 17 in favor and one abstention.
The FDA panel accepted Pfizer's data indicating the vaccine is safe and 90.7% effective in preventing COVID-19 infections in this age group.
The agency typically goes along with the advice of its expert panels, though it isn't bound to do so. It will issue a decision within the next several days. If the FDA authorizes the vaccine for these younger children, as seems likely, another panel of experts advising the Centers for Disease Control and Prevention would make its own recommendations and offer guidelines next week on its use among this age group.
The vaccine provides a broad defense against COVID-19 and "effectively neutralized the delta variant" in young kids, said , senior vice president of vaccine
You’re reading a preview, subscribe to read more.
Start your free 30 days